Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Top Cited Papers
Open Access
- 1 March 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (9), 1981-1987
- https://doi.org/10.1182/blood-2011-08-358135
Abstract
A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP. In CP, the 8-year survival was ≤ 15% before 1983, 42%-65% from 1983-2000, and 87% since 2001. Survival was worse in older patients (P = .004), but this was less significant since 2001 (P = .07). Survival by Sokal risk was significantly different before 2001 (P < .001), but not since 2001 (P = .4). In AP, survival improved over time (P < .001); the 8-year survival in patients treated since 2001 was 75%. Survival by age was not different in years < 2001 (P = .09), but was better since 2001 in patients ≤ 70 years of age (P = .004). In BP, the median survival improved over time (P < .001), although it has been only 7 months since 2001. In summary, survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML. Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML.Keywords
This publication has 15 references indexed in Scilit:
- Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008Journal of Clinical Oncology, 2011
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseJournal of Clinical Oncology, 2010
- Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population levelHaematologica, 2008
- Cytogenetic and molecular responses and outcome in chronic myelogenous leukemiaCancer, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trialsBlood, 2006
- Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-? regimens for early chronic phaseCancer, 2003
- Characteristics of accelerated disease in chronic myelogenous leukemiaCancer, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958